BioSpace News Archive

ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock. In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold

Be The Match® announced the appointment of Amy Ronneberg as chief executive officer —the first female CEO for the organization.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced it will host an investor conference call to discuss the detailed results from the Phase 3 PEGASUS study evaluating pegcetacoplan (APL-2),

CELLUM BioMedical, a CLIA licensed laboratory and bio technology company, announced that it will begin offering specimen & serological antibody testing for SARS-CoV-2, the virus that causes COVID-19, to hospitals, healthcare organizations and businesses looking to reopen throughout the nation.

Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo® (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy

Mesenchymal stem cells (MSCs) are multipotent in that they naturally replenish the cell types that build our bone, cartilage and adipose tissues

Researchers at the University of Maryland School of Medicine (UMSOM) have identified how certain gene mutations cause amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, has entered into a strategic partnership agreement with Thermo Fisher Scientific (“Thermo Fisher”). With plans to build on the sequencer Genetron S5 (Registration Number 20193220820), the partnership aims to enhance innovation, commercialization and promotion of next-generation sequencing (NGS) platforms in

Sorrento Therapeutics, Inc. announced that an Application for Emergency Use Authorization is under review at the U.S. Food and Drug Administration for its COVI-TRACKTMin vitro diagnostic test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus.

Governments around the world have achieved various levels of success in using lockdown and social distancing to stop the spread of the Coronavirus within the community and to deal with the COVID-19 pandemic.